# Avidination for RadionuclideTHerapy in Nonpalpable Breast Cancer

> **NCT06390241** · PHASE1 · TERMINATED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 18 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Avidin-biotin-Dota-90Y

## Key facts

- **NCT ID:** NCT06390241
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-06-19
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Target enrolment was not met. The trial is terminated because the radiopharmaceutical is not produced under GMP
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06390241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06390241, "Avidination for RadionuclideTHerapy in Nonpalpable Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06390241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*